Links

Homepage

Stock List

Search by Ticker

News

Login

Profound Medical Corp (TSX:PRN)
Stock Analysis

PRN.TO13.7
▼ -3.66%-0.52

Stock Analysis

The following stock analysis is based on 4.7 years of data (i.e. since Jul 10, 2018). All the stock history has been downloaded.

Stock Exchange

Profound Medical Corp trades on the Toronto exchange in CAD dollars.

Sector

It is in the healthcare sector.

Current Status of Profound Medical Corp

It is currently trading at $13.7 ($14.22 the previous day).

Financials

The current Canada / US exchange rate is 1.36527.



Will This Trend Continue?

The year over year average increase is 10.4% per year assuming steady exponential growth. The actual 5 year average is 23. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year10.242542372881-49.2- Below Average
2 year20.147210743802-14.8- Below Average
3 year23.637977099237104.3+ Above Average
4 year11.57151639344351.7+ Above Average
5 year7.62653631284920- Below Average

Risk

The worst drop it has had in recent years is -87.1%. It has a shape to the stock curve, which means

Stock shape test

DAYS AG0PRICE
1016.57DROPPING
3017.3DROPPING
6013.84RISING
1505.65RISING
36511.95DROPPING
80027DROPPING
120011RISING
16006.2RISING
2000RISING


With an average increase of 10.4% year over year, if Profound Medical Corp is bought at the worst time, Stockmarketizer analysts estimate it will take 100.5 months before the stock will recover to the original purchase price.

Tradingview BuySell Widget

Yahoo News Feed

Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results

Tue, 07 Mar 2023 21:05:00 Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSATORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation ...... Read Full Article

Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

Wed, 01 Mar 2023 21:30:00 TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and ...... Read Full Article

Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow

Tue, 14 Feb 2023 21:30:00 TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and ...... Read Full Article

Profound Medical to Present at the 2022 Jefferies London Healthcare Conference

Tue, 08 Nov 2022 21:30:00 TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and ...... Read Full Article

Profound Medical Announces Third Quarter 2022 Financial Results

Thu, 03 Nov 2022 20:05:00 TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the ...... Read Full Article

Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

Thu, 13 Oct 2022 20:30:00 TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2022 financial ...... Read Full Article

Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer

Mon, 26 Sep 2022 12:00:00 TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that updated results from the ...... Read Full Article

Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

Thu, 15 Sep 2022 12:00:00 TORONTO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced changes to its management ...... Read Full Article

Profound Medical to Participate in September Investor Conferences

Tue, 06 Sep 2022 20:30:00 TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate ...... Read Full Article

Profound Medical Provides TULSA-PRO® Reimbursement Update

Fri, 02 Sep 2022 16:05:00 TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a U.S. reimbursement ...... Read Full Article

Profound Medical Announces Second Quarter 2022 Financial Results

Thu, 04 Aug 2022 20:05:00 TORONTO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the ...... Read Full Article

Profound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to Follow

Thu, 14 Jul 2022 20:30:00 TORONTO, July 14, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2022 financial ...... Read Full Article

Profound Medical to Participate in the Cowen 7th Annual FutureHealth Conference

Thu, 16 Jun 2022 20:30:00 TORONTO, June 16, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and ...... Read Full Article

What You Need To Know About Profound Medical Corp.'s (TSE:PRN) Investor Composition

Tue, 07 Jun 2022 11:56:26 A look at the shareholders of Profound Medical Corp. ( TSE:PRN ) can tell us which group is most powerful. Large...... Read Full Article

Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference

Thu, 02 Jun 2022 20:30:00 TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present ...... Read Full Article

Profound Medical Annual and Special Meeting of Shareholders Voting Results

Wed, 18 May 2022 21:43:00 TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 12,858,319 ...... Read Full Article

Profound Medical Clarifies Recent Insider Buying

Wed, 18 May 2022 20:30:00 TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its insiders, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) ...... Read Full Article

TULSA-PRO® Was Front and Center at AUA2022

Tue, 17 May 2022 21:25:00 Activities Highlighting Profound’s Ground-Breaking Technology Included a Semi-Live TULSA Procedure Performed by UT Southwestern’s Dr. Kenneth A. Goldberg During Meeting’s Plenary SessionTORONTO, May 17, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), ...... Read Full Article

Trade Alert: The Independent Lead Director Of Profound Medical Corp. (TSE:PRN), Brian Ellacott, Has Just Spent US$459k Buying 278% More Shares

Sun, 15 May 2022 12:08:33 Potential Profound Medical Corp. ( TSE:PRN ) shareholders may wish to note that the Independent Lead Director, Brian...... Read Full Article

Profound Medical Announces First Quarter 2022 Financial Results

Mon, 09 May 2022 20:05:00 TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the ...... Read Full Article
<